e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Interstitial lung diseases II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum exosomes from IPF patients display a fibrotic miRNA profile that correlates to clinical measures of disease severity
Paul Minnis (Bangor, United Kingdom), Paul Minnis, Rosemary Kane, Rachel Anglin, Sinead Walsh, Julie Worrel, Faheem Khan, Robert V. Lumsden, Sharon Whitty, Michael P. Keane
Source:
International Congress 2015 – Interstitial lung diseases II
Session:
Interstitial lung diseases II
Session type:
Thematic Poster Session
Number:
3845
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Paul Minnis (Bangor, United Kingdom), Paul Minnis, Rosemary Kane, Rachel Anglin, Sinead Walsh, Julie Worrel, Faheem Khan, Robert V. Lumsden, Sharon Whitty, Michael P. Keane. Serum exosomes from IPF patients display a fibrotic miRNA profile that correlates to clinical measures of disease severity. Eur Respir J 2015; 46: Suppl. 59, 3845
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Increased levels of glycosaminoglycans in lungs from patients with IPF
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
Distinct gene expression profiles of cultured stromal cells from the patients with idiopathic pulmonary fibrosis and lung adenocarcinoma
Source: International Congress 2015 – Translational studies in airway cell biology
Year: 2015
Distinct clinical and pathological phenotypes in IPF
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Discovery and validation of peripheral blood gene expression profiles predictive of poor outcome and disease progression in idiopathic pulmonary fibrosis
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014
Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Severe lung inflammation is a feature of IPF
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Plasma protein signature of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013
Does apoptosis evasion only affect fibroblasts from idiopathic pulmonary fibrosis?
Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Year: 2013
Prevalence and trafficking of circulating fibrocytes in smoking-related fibrogenic lung diseases
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Plasma mitochondrial DNA as a biomarker of disease progression in idiopathic pulmonary fibrosis
Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias
Year: 2018
IGFBP-2 a new interesting target in IPF
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE)
Source: International Congress 2015 – IPF pathogenesis
Year: 2015
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
Longitudinal serological assessment of neutrophil activity is related to disease progression in idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
Late Breaking Abstract - Prognostic value of serum biomarkers in patients with idiopathic pulmonary fibrosis and correlation with disease progression.
Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases
Year: 2021
IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 373s
Year: 2007
Serum IGFBP2 as a marker of idiopathic pulmonary fibrosis
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept